CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2015-2017

3.2.2.1. Competitive intelligence and strategies of companies

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Surge in incidence of infectious diseases
3.3.1.2. Increase in R&D activities for the development of combination drugs
3.3.1.3. Rise in funding for the development of antibiotics

3.3.2. Restraints

3.3.2.1. Side effects associated with cephalosporins
3.3.2.2. Antibiotic resistance to cephalosporins

3.3.3. Opportunities

3.3.3.1. Lucrative opportunities in the emerging economies

3.4. MARKET SHARE ANALYSIS, 2016
3.5. PORTERS FIVE FORCES ANALYSIS
3.6. NOVEL MOLECULES IN CEPHALOSPORIN MARKET

3.6.1. CEFTAZIDIME
3.6.2. CEFUROXIME

3.7. COMBINATION THERAPIES IN CEPHALOSPORIN MARKET

CHAPTER 4 CEPHALOSPORIN MARKET, BY GENERATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. FIRST-GENERATION CEPHALOSPORIN

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. SECOND-GENERATION CEPHALOSPORIN

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. THIRD-GENERATION CEPHALOSPORIN

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. FOURTH-GENERATION CEPHALOSPORIN

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. FIFTH-GENERATION CEPHALOSPORIN

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

CHAPTER 5 CEPHALOSPORIN MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. BRANDED CEPHALOSPORIN DRUGS

5.2.1. Market size and forecast

5.3. GENERIC CEPHALOSPORIN DRUGS

5.3.1. Market size and forecast

CHAPTER 6 CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. CEPHALOSHORIN INJECTIONS

6.2.1. Market size and forecast

6.3. ORAL CEPHALOSPORIN DRUGS

6.3.1. Market size and forecast

CHAPTER 7 CEPHALOSPORIN MARKET, BY APPLICATION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. RESPIRATORY TRACT INFECTION

7.2.1. Market size and forecast

7.3. SKIN INFECTION

7.3.1. Market size and forecast

7.4. EAR INFECTION

7.4.1. Market size and forecast

7.5. URINARY TRACT INFECTION

7.5.1. Market size and forecast

7.6. SEXUALLY TRANSMITTED INFECTION

7.6.1. Market size and forecast

7.7. OTHERS

7.7.1. Market size and forecast

CHAPTER 8 CEPHALOSPORIN MARKET, BY REGION

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Growth factors and opportunities
8.2.3. North America cephalosporin market by country

8.2.3.1. U.S.

8.2.3.1.1. U.S. cephalosporin market by generation
8.2.3.1.2. U.S. cephalosporin market by type
8.2.3.1.3. U.S. cephalosporin market by route of drug administration
8.2.3.1.4. U.S. cephalosporin market by application

8.2.3.2. Canada

8.2.3.2.1. Canada cephalosporin market by generation
8.2.3.2.2. Canada cephalosporin market by type
8.2.3.2.3. Canada cephalosporin market by route of drug administration
8.2.3.2.4. Canada cephalosporin market by application

8.2.3.3. Mexico

8.2.3.3.1. Mexico cephalosporin market by generation
8.2.3.3.2. Mexico cephalosporin market by type
8.2.3.3.3. Mexico cephalosporin market by route of drug administration
8.2.3.3.4. Mexico cephalosporin market by application

8.2.4. North America cephalosporin market by generation
8.2.5. North America cephalosporin market by type
8.2.6. North America cephalosporin market by route of drug administration
8.2.7. North America cephalosporin market by application

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Growth factors and opportunities
8.3.3. Europe cephalosporin market by country

8.3.3.1. Germany

8.3.3.1.1. Germany cephalosporin market by generation
8.3.3.1.2. Germany cephalosporin market by type
8.3.3.1.3. Germany cephalosporin market by route of drug administration
8.3.3.1.4. Germany cephalosporin market by application

8.3.3.2. France

8.3.3.2.1. France cephalosporin market by generation
8.3.3.2.2. France cephalosporin market by type
8.3.3.2.3. France cephalosporin market by route of drug administration
8.3.3.2.4. France cephalosporin market by application

8.3.3.3. UK

8.3.3.3.1. UK cephalosporin market by generation
8.3.3.3.2. UK cephalosporin market by type
8.3.3.3.3. UK cephalosporin market by route of drug administration
8.3.3.3.4. UK cephalosporin market by application

8.3.3.4. Italy

8.3.3.4.1. Italy cephalosporin market by generation
8.3.3.4.2. Italy cephalosporin market by type
8.3.3.4.3. Italy cephalosporin market by route of drug administration
8.3.3.4.4. Italy cephalosporin market by application

8.3.3.5. Spain

8.3.3.5.1. Spain cephalosporin market by generation
8.3.3.5.2. Spain cephalosporin market by type
8.3.3.5.3. Spain cephalosporin market by route of drug administration
8.3.3.5.4. Spain cephalosporin market by application

8.3.3.6. Rest of Europe

8.3.3.6.1. Rest of Europe cephalosporin market by generation
8.3.3.6.2. Rest of Europe cephalosporin market by type
8.3.3.6.3. Rest of Europe cephalosporin market by route of drug administration
8.3.3.6.4. Rest of Europe cephalosporin market by application

8.3.4. Europe cephalosporin market by generation
8.3.5. Europe cephalosporin market by type
8.3.6. Europe cephalosporin market by route of drug administration
8.3.7. Europe cephalosporin market by application

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Growth factors and opportunities
8.4.3. Asia-Pacific cephalosporin market by country

8.4.3.1. Japan

8.4.3.1.1. Japan cephalosporin market by generation
8.4.3.1.2. Japan cephalosporin market by type
8.4.3.1.3. Japan cephalosporin market by route of drug administration
8.4.3.1.4. Japan cephalosporin market by application

8.4.3.2. China

8.4.3.2.1. China cephalosporin market by generation
8.4.3.2.2. China cephalosporin market by type
8.4.3.2.3. China cephalosporin market by route of drug administration
8.4.3.2.4. China cephalosporin market by application

8.4.3.3. India

8.4.3.3.1. India cephalosporin market by generation
8.4.3.3.2. India cephalosporin market by type
8.4.3.3.3. India cephalosporin market by route of drug administration
8.4.3.3.4. India cephalosporin market by application

8.4.3.4. Australia

8.4.3.4.1. Australia cephalosporin market by generation
8.4.3.4.2. Australia cephalosporin market by type
8.4.3.4.3. Australia cephalosporin market by route of drug administration
8.4.3.4.4. Australia cephalosporin market by application

8.4.3.5. South Korea

8.4.3.5.1. South Korea cephalosporin market by generation
8.4.3.5.2. South Korea cephalosporin market by type
8.4.3.5.3. South Korea cephalosporin market by route of drug administration
8.4.3.5.4. South Korea cephalosporin market by application

8.4.3.6. Rest of Asia-Pacific

8.4.3.6.1. Rest of Asia-Pacific cephalosporin market by generation
8.4.3.6.2. Rest of Asia-Pacific cephalosporin market by type
8.4.3.6.3. Rest of Asia-Pacific cephalosporin market by route of drug administration
8.4.3.6.4. Rest of Asia-Pacific cephalosporin market by application

8.4.4. Asia-Pacific cephalosporin market by generation
8.4.5. Asia-Pacific cephalosporin market by type
8.4.6. Asia-Pacific cephalosporin market by route of drug administration
8.4.7. Asia-Pacific cephalosporin market by application

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Growth factors and opportunities
8.5.3. LAMEA cephalosporin market by country

8.5.3.1. Brazil

8.5.3.1.1. Brazil cephalosporin market by generation
8.5.3.1.2. Brazil cephalosporin market by type
8.5.3.1.3. Brazil cephalosporin market by route of drug administration
8.5.3.1.4. Brazil cephalosporin market by application

8.5.3.2. South Africa

8.5.3.2.1. South Africa cephalosporin market by generation
8.5.3.2.2. South Africa cephalosporin market by type
8.5.3.2.3. South Africa cephalosporin market by route of drug administration
8.5.3.2.4. South Africa cephalosporin market by application

8.5.3.3. Saudi Arabia

8.5.3.3.1. Saudi Arabia cephalosporin market by generation
8.5.3.3.2. Saudi Arabia cephalosporin market by type
8.5.3.3.3. Saudi Arabia cephalosporin market by route of drug administration
8.5.3.3.4. Saudi Arabia cephalosporin market by application

8.5.3.4. Rest of LAMEA

8.5.3.4.1. Rest of LAMEA cephalosporin market by generation
8.5.3.4.2. Rest of LAMEA cephalosporin market by type
8.5.3.4.3. Rest of LAMEA cephalosporin market by route of drug administration
8.5.3.4.4. Rest of LAMEA cephalosporin market by application
8.5.4. LAMEA cephalosporin market by generation

8.5.5. LAMEA cephalosporin market by type
8.5.6. LAMEA cephalosporin market by route of drug administration
8.5.7. LAMEA cephalosporin market by application

CHAPTER 9 COMPANY PROFILES

9.1. ALLERGAN PLC

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. BRISTOL-MYERS SQUIBB COMPANY

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segment
9.2.4. Business performance

9.3. ELI LILLY AND COMPANY

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance

9.4. F. HOFFMANN-LA ROCHE AG

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5. GLAXOSMITHKLINE PLC

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance

9.6. LUPIN LIMITED (LUPIN PHARMACEUTICALS, INC.)

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance

9.7. MERCK & CO., INC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. PFIZER INC.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. SANOFI

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments